Pharmasset (VRUS) 136.99 0.00

Pharmasset, Inc.
(VRUS) 136.99 0.00

Last Trade:	136.97	Day Range:	136.97 - 136.97
Trade Time:	Jan 17	52wk Range:	47.40 - 137.81
Prev. Close:	136.97	Market Cap:	10.36B
Open:	0.00	Div Yield:	0
Volume:	0	PE:	-1100
EPS:	-1.25

The Latest On VRUS

BioLineRx Surges after Hep C License Agreement 1/24/12 10:23am

Achillion's Hep C Pipeline Likely Can't Compete 1/19/12 9:03am

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12 2:54pm

Forget Dendreon, Inhibitex is the New Biotech Success Story 1/9/12 1:26pm

Best Biotech Stocks of 2011 12/27/11 10:39am

Wedbush Securities Drops Coverage on Pharmasset on Pending Gilead Acquisition 12/16/11 4:24pm

Robert W. Baird Downgrades Pharmasset to Neutral 12/16/11 10:51am

JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement 12/16/11 9:50am

Pharmasset Announces Intent to Amend QUANTUM Trial 12/16/11 8:00am

Want More Tech ETFs? Global X Has Your Back 12/6/11 2:58pm

Citi Reiterates Buy, $49 PT on Gilead 12/5/11 12:11pm

J.P. Morgan Reiterates Overweight On Gilead 12/5/11 12:07pm

BioLineRx Surges after Hep C License Agreement 1/24/12

Achillion's Hep C Pipeline Likely Can't Compete 1/19/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Forget Dendreon, Inhibitex is the New Biotech Success Story 1/9/12

Best Biotech Stocks of 2011 12/27/11

Wedbush Securities Drops Coverage on Pharmasset on Pending Gilead Acquisition 12/16/11

Robert W. Baird Downgrades Pharmasset to Neutral 12/16/11

JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement 12/16/11

Pharmasset Announces Intent to Amend QUANTUM Trial 12/16/11

Want More Tech ETFs? Global X Has Your Back 12/6/11

Citi Reiterates Buy, $49 PT on Gilead 12/5/11

J.P. Morgan Reiterates Overweight On Gilead 12/5/11

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Forget Dendreon, Inhibitex is the New Biotech Success Story 1/9/12

Best Biotech Stocks of 2011 12/27/11

Want More Tech ETFs? Global X Has Your Back 12/6/11

Citi Reiterates Buy, $49 PT on Gilead 12/5/11

J.P. Morgan Reiterates Overweight On Gilead 12/5/11

Brean Murray Raises Inhibitex PT to $19 From $12 11/29/11

Deutsche Bank Has Buy, $53 PT On Gilead 11/28/11

Brean Murray Downgrades Pharmasset to "Hold" 11/22/11

Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs 11/22/11

Hep-C Stocks Soar On M&A News 11/21/11

Financial Breakfast: Morning News Summary for November 21, 2011 11/21/11

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Wedbush Securities Drops Coverage on Pharmasset on Pending Gilead Acquisition 12/16/11

Robert W. Baird Downgrades Pharmasset to Neutral 12/16/11

JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement 12/16/11

Citi Reiterates Buy, $49 PT on Gilead 12/5/11

J.P. Morgan Reiterates Overweight On Gilead 12/5/11

Brean Murray Raises Inhibitex PT to $19 From $12 11/29/11

Deutsche Bank Has Buy, $53 PT On Gilead 11/28/11

End-of-Day Market Summary for November 22, 2011 11/22/11

UPDATE: Canaccord Downgrades Pharmasset to Hold, Ups PT to $137 on Announced Deal 11/22/11

Brean Murray Downgrades Pharmasset to "Hold" 11/22/11

Brean Murray Downgrades Pharmasset to Hold, Removes PT 11/22/11

Trade VRUS
NOW!

Partner Headlines

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, Inhibitex, Gilead Sciences and Pharmasset - Press Releases 1/10/12

Eyeing Hepatitis C, Bristol-Myers Snatches Inhibitex for $2B 1/9/12

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale) 1/9/12

BMY Kicks Off 2012 Pharma Deals - Analyst Blog 1/9/12

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale) 1/9/12

Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion 1/7/12

Inhibitex Shares Whipsawed by Cautious Analyst Comment 1/4/12

'Fast Money' Recap: Beaten-Up Financials Eyed 12/22/11

Analysts' Actions: GRPN, VRUS, MU, CVC 12/19/11

Press Releases

Gilead Sciences Completes Acquisition of Pharmasset, Inc. 1/17/12 Business Wire Story

Gilead Sciences Completes Tender Offer for All Outstanding Shares of Pharmasset, Inc. 1/12/12 Business Wire Story

Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period 1/6/12 Business Wire Story

Pharmasset Announces Intent to Amend QUANTUM Trial 12/16/11 Newswire Story

Quarterly Changes to the NASDAQ Q-50 Index 12/9/11 GlobeNewswire Story

HYSR, GEDU and VRUS are the Stocks to Watch for November 22nd from OTCPicks.com 11/22/11 Emailwire Story

Ryan & Maniskas, LLP Announces Investigation of Pharmasset, Inc. 11/21/11 Business Wire Story

The Law Firm of Weiss & Lurie Investigates Pharmasset, Inc. 11/21/11 Business Wire Story

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Pharmasset, Inc. 11/21/11 Business Wire Story

Pharmasset, Inc. Shareholder Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate the Board of Pharmasset, Inc. Concerning the Sale of Pharmasset to Gilead Sciences, Inc. 11/21/11 Newswire Story

The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Pharmasset, Inc. in Connection with the Sale of the Company to Gilead Sciences, Inc. 11/21/11 Newswire Story

Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion 11/21/11 Business Wire Story

Get the latest VRUS stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Pharmasset, Inc. stock price.

Pharmasset, Inc. by YCharts

Pharmasset (VRUS) 136.99 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On VRUS

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social